Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasisSima Rafati
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, 69 Pasteur Ave, Tehran 13164, Iran
Clin Vaccine Immunol 13:1104-10. 2006
..These data suggest that the amastin signature peptide could represent a relevant biomarker for the serodiagnosis of VL and, most importantly, that it could permit differentiation among the different stages of the disease...
Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantumSima Rafati
Molecular Immunology Lab, Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
Vaccine 23:3716-25. 2005
..We propose that the combination of DNA and recombinant protein vaccination using CPs could be instrumental to control (VL) in dogs...
- Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients
Sima Rafati
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
Vaccine 25:4159-69. 2007
..This study demonstrates the potential of HSP70 in stimulating humoral responses in humans and mice and indicates there is a need to further explore and examine the value of this important molecule in the control of leishmaniasis...
Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice modelAzam Bolhassani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, 69 Pasteur Ave, Tehran, Iran
Exp Parasitol 128:9-17. 2011
..These results suggest that the development of DNA vaccines encoding VP22 fused to a target Leishmania antigen would be a promising strategy to improve immunogenicity and DNA vaccine potency...
- Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals
Naghmeh Khoshgoo
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Vaccine 26:5822-9. 2008
..The achieved result is highly encouraging the use of cysteine proteinases types I, II and III as vaccine candidate against visceral leishmaniasis...
- C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice
Delaram Doroud
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
PLoS Negl Trop Dis 5:e1236. 2011
..Therefore, undefined effect of cationic solid lipid nanoparticles (cSLN) as an adjuvant in enhancing the immune response toward leishmanial antigens led us to refocus our vaccine development projects...
- Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population
Alireza Nakhaee
Department of Clinical Biochemistry, School of Medical Sciences, Tarbiat Modarres University, Tehran, Iran
Vet Parasitol 119:107-23. 2004
..We showed the importance of CPB and CTE in particular as a target of immune response and their potential use for serodiagnosis in asymptomatic dogs...
- Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice
Sima Rafati
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Exp Parasitol 118:393-401. 2008
..This study demonstrated that immunization with CTE display both type 1 and 2 immune signatures in experimental murine model of L. infantum infection...
- Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis
Amir Mizbani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Vaccine 28:53-62. 2009
..All together, these results indicate the promise of A2-expressing L. tarentolae as a safe live vaccine against visceral leishmaniasis...
- Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity
Tahereh Taheri
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
Exp Parasitol 126:135-45. 2010
..g. in differentiation and survival of amastigotes. Apparently, the SPase I expression is not essential for in vitro growth of the parasite...
- Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies
Azam Bolhassani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Vaccine 26:3362-70. 2008
..Our study demonstrated that co-delivery of E7+Gp96 as DNA/DNA and E7+CT-gp96 as DNA/protein could be an effective approach to induce E7-specific immune responses as a potential vaccine candidate for cervical cancer...
- Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasis
Sima Rafati
Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
Mol Biochem Parasitol 135:13-20. 2004
..Therefore, the Leishmania signal peptidase, albeit localised intracellularly, is a significant target of the Leishmania specific immune response and highlights its potential use for serodiagnosis of cutaneous and visceral leishmaniasis...
- Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice
Sima Rafati
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
Vaccine 24:3290-7. 2006
..However, our results indicated that DNA/DNA strategy developed more effective protective responses than the other two approaches and induced 81% reduction in L. major parasite load...
- Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection
Delaram Doroud
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
J Control Release 153:154-62. 2011
..The nanomedical feature of this novel formulation can be applied for wide-spread use in genetic vaccination against leishmaniasis, which is currently managed only through relatively ineffectual therapeutic regimens...
- Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies
Azam Bolhassani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Exp Parasitol 127:637-45. 2011
....
- Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis
Sima Rafati
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
Exp Parasitol 103:143-51. 2003
..Furthermore, the asymptomatic dogs in contrast to the symptomatic cases exhibited specific lymphocyte proliferation to both crude antigens and rCPs...
- Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections
Elham Mohit
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
Mol Immunol 53:149-60. 2013
..Therefore, this approach suggests a combinational therapeutic strategy against cervical and other HPV-related cancers...
- Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis
Narges Abdian
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
Exp Parasitol 127:627-36. 2011
..Therefore, we recommend further investigations on the usage of LPG3 co-delivery with candidate antigens for vaccine development against leishmaniasis...
- Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis
Azita Zadeh-Vakili
Department of Immunology, Pasteur Institute of Iran, P.O. Box 11365-6699, Tehran, Iran
Vaccine 22:1930-40. 2004
....
- Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis
Sima Rafati
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
Vaccine 24:2169-75. 2006
....
- Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations
Delaram Doroud
Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
J Pharm Pharm Sci 13:320-35. 2010
....
- Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7
Jafar Amani
Applied Biotechnology Research Center, Baqiyatallah Medical Science University, Tehran, Iran
Vaccine 28:6923-9. 2010
..coli. The immunization was conducted in mice with purified rEIT. The results showed that this chimeric protein induced strong humoral response as well as protection against live challenges using EHEC...
- In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response
Negar Seyed
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
PLoS Negl Trop Dis 5:e1295. 2011
..The first step toward a peptide vaccine is epitope mapping of different proteins according to the most frequent HLA types in a population...
- Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae
Amir Mizbani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Parasitol Res 109:793-9. 2011
..Altogether, our results show that A2 is functional in L. tarentolae, although through an unknown mechanism, and loss of A2 has been one of the factors partly contributing to the loss of virulence of L. tarentolae...
- Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients
Azam Bolhassani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Indian J Med Res 130:533-41. 2009
..The aim of the present investigation was to determine and search for serologic markers in cervical cancer patients associated with HPV...
- The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen
Azam Bolhassani
Pasteur Institute of Iran, Tehran, Iran
Drug Deliv 16:196-204. 2009
..Therefore, this new delivery system could have promising applications in gene therapy...
- Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model
Maryam Salehi
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Immunotherapy 4:1107-20. 2012
..Cervical cancer, the third most prevalent cause of cancer in women worldwide, is associated with HPVs. The critical role of E7 protein in HPV-related malignancies has designated it as a strong contender for generating vaccines against HPV...
- Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice
Jafar Amani
Department of Plant Biotechnology, National Institute of Genetic Engineering and Biotechnology NIGEB, Tehran, Iran
Plant Sci 180:620-7. 2011
..coli O157:H7 significantly exhibited reduced bacterial shedding. Application of transgenic plants containing trivalent immunogen is an effective tool for protection against E. coli O157:H7...
- Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems
Delaram Doroud
Quality Control Department, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran
Expert Rev Vaccines 11:69-86. 2012
....
- Improvement of different vaccine delivery systems for cancer therapy
Azam Bolhassani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Mol Cancer 10:3. 2011
..This review will focus on the utilization of different vaccine delivery systems for prevention or treatment of cancer. We will discuss their clinical applications and the future prospects for cancer vaccine development...
- Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice
Arash Arashkia
Hepatitis and AIDS Department NRGB Lab, Pasteur Institute of Iran, Pasteur Ave, Tehran 1316943551, Iran
Virus Genes 40:44-52. 2010
....
- Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model
Amin Daemi
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
Immunol Lett 148:117-25. 2012
..Altogether, our results show that comparable regions of gp96 (N-/C-terminal fragments of gp96) may have qualitatively different immunological effects in vaccine design...
- Leishmaniasis vaccine candidates for development: a global overview
Ali Khamesipour
Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
Indian J Med Res 123:423-38. 2006
..This is not an exhaustive review of vaccine discovery or the principles of clinical immunology underlying vaccine development...
- Different spectra of therapeutic vaccine development against HPV infections
Azam Bolhassani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Hum Vaccin 5:671-89. 2009
..Human trials are the most important test for the efficacy of HPV16/18 E6 and E7 proteins as immunotherapy for cervical cancer. This review attempts to describe different therapeutic vaccinations against HPV infections...
- Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy
Nariman Aghaei Bandbon Balenga
Department of Biotechnology, Faculty of Science, University of Tehran, Tehran, Iran
J Biotechnol 124:602-14. 2006
..Also higher amounts of DNA contributed to stronger Th1 response...
- Heat-shock proteins as powerful weapons in vaccine development
Azam Bolhassani
Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
Expert Rev Vaccines 7:1185-99. 2008
..Their ability in eliciting immune responses against different pathogens (parasite and virus) and their role in cancer immunity will be discussed in this review...
- Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation
Sima Rafati
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
Vaccine 20:2439-47. 2002
..Taken together, it was shown that the induced partial protection was mainly dependent on IFN-gamma producing CD8(+) T cells...
- Chemokine-based immunotherapy: delivery systems and combination therapies
Elham Mohit
Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran 13164, Iran
Immunotherapy 4:807-40. 2012
..In this review, several chemokines with their role in inducing immune response against different diseases are discussed, with a major emphasis on cancer...
- In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications
Jafar Amani
National Institute of Genetic Engineering and Biotechnology, Shahrak e Pajoohesh, 15th Km, Tehran Karaj Highway, Tehran, IR, Iran
Theor Biol Med Model 6:28. 2009
..Among these proteins, Intimin, Tir, and EspA, which are expressed by attaching-effacing genes, are responsible for the attachment to epithelial cell that leads to lesions...
- Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis
Herve Pascalis
Immunologie des Leishmanioses, Institut Pasteur de le Guyane Française, Institut d Etudes Supérieures de la Guyane, Universite Antilles Guyane, Cayenne, French Guiana
Infect Immun 71:2924-6. 2003
..The results suggest that CPs would be quite good candidates for a vaccine against different Leishmania species...
- Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice
Majid Golkar
CNRS UMR 5163 Université Joseph Fourier, UFR de Biologie, Institut Jean Roget, Campus Sante, Domaine de la Merci BP 170, 38042 Grenoble Cedex 09, France
Vaccine 25:4301-11. 2007
..This study shows the protective efficacy of recombinant GRA2 against chronic infection by T. gondii and confirms the utility of MPL adjuvant in enabling a vaccine candidate to induce a protective Th1 immune response...
- The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women
Majid Golkar
CNRS UMR 5163, UFR de Biologie, Institut Jean Roget, Universite Joseph Fourier, Campus Sante, Domaine de la Merci, and Parasitology and Mycology Laboratory, Grenoble Teaching Hospital A Michallon, Grenoble Cedex 09, France
Diagn Microbiol Infect Dis 58:419-26. 2007
..4% (sera collected in Iran) for sera of chronic infection. The recombinant GRA2 could thus advantageously complement previously described T. gondii antigens for the serodiagnosis of acute Toxoplasma infection...
- Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis
Adnene Salhi
Institut National de la Santé et de la Recherche Médicale U399, Faculty of Medicine, 17 Boulevard Jean Moulin, Marseille Cedex 05, France
J Immunol 180:6139-48. 2008
..These observations demonstrate an important role for IL-10 in skin lesions in humans infected with L. braziliensis, and identify circulating monocytes and Tregs as principal sources of IL-10 in these patients...
